Literature DB >> 27058198

Seizure outcomes after stereotactic radiosurgery for the treatment of cerebral arteriovenous malformations.

Benjamin J Ditty1, Nidal B Omar1, Paul M Foreman1, Joseph H Miller1, Kimberly P Kicielinski1, Winfield S Fisher1, Mark R Harrigan1.   

Abstract

OBJECTIVE Patients with cerebral arteriovenous malformations (AVMs) commonly present with seizure. Seizure outcomes in patients treated with stereotactic radiosurgery (SRS) are poorly defined. A case series of patients with cerebral AVMs treated with SRS is presented to evaluate long-term seizure outcome. METHODS A retrospective review of the medical record was performed, identifying 204 consecutive patients with AVMs treated with SRS between January 1991 and June 2012. Clinical and radiographic data were evaluated. Seizure outcome was measured using the Engel Epilepsy Surgery Outcome Scale. Mean duration of follow-up was 37.1 months (SD 38.3 months) with a minimum follow-up period of 1 month. RESULTS Of the 204 patients with cerebral AVMs treated with SRS, 78 patients (38.2%) presented with seizures and 49 of those patients were treated with antiepileptic drugs (AEDs). Following SRS, 63 (80.8%) of the 78 patients who had had seizures prior to SRS were seizure-free at a mean follow-up time of 37.2 months (SD 41.3 months). Of the 49 patients who had been treated with AEDs, 17 were still taking AEDs at last follow-up. Of the 126 patients who did not present with seizures prior to treatment with SRS, only 5 patients (4.0%) had seizures in the post-SRS period. There was no significant correlation between post-SRS seizure status and patient demographic features, comorbidities, AVM characteristics, history of operative intervention, pre- or posttreatment hemorrhage, or radiographic degree of AVM resolution. CONCLUSIONS Stereotactic radiosurgery for treatment of cerebral AVMs is effective at providing long-term control of seizures. A substantial number of patients who were treated with SRS were not only seizure free at their last follow-up, but had been successfully weaned from antiepileptic medications.

Entities:  

Keywords:  AED = antiepileptic drug; AVM; AVM = arteriovenous malformation; CTA = CT angiography; DSA = digital subtraction angiography; ICH = intracerebral hemorrhage; SRS = stereotactic radiosurgery; arteriovenous malformation; seizure; stereotactic radiosurgery; vascular disorders

Mesh:

Substances:

Year:  2016        PMID: 27058198     DOI: 10.3171/2015.12.JNS152461

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  5 in total

1.  Seizure predictors and outcome after Onyx embolization in patients with brain arteriovenous malformations.

Authors:  Baorui Zhang; Xin Feng; Fei Peng; Luyao Wang; Er Kang Guo; Yupeng Zhang; Peng Liu; Zhongxue Wu; Aihua Liu
Journal:  Interv Neuroradiol       Date:  2018-09-30       Impact factor: 1.610

2.  Radiosurgical treatment of arteriovenous malformations in a retrospective study group of 33 children: the importance of radiobiological scores.

Authors:  Jody Filippo Capitanio; Pietro Panni; Alberto Luigi Gallotti; Carmen Rosaria Gigliotti; Francesco Scomazzoni; Stefania Acerno; Antonella Del Vecchio; Pietro Mortini
Journal:  Childs Nerv Syst       Date:  2018-11-24       Impact factor: 1.475

Review 3.  Recent advances in epilepsy.

Authors:  Mark Manford
Journal:  J Neurol       Date:  2017-01-24       Impact factor: 4.849

4.  Benefits from Exclusion Treatment of Unruptured Brain Arteriovenous Malformations on Epilepsy in Adults.

Authors:  Romain Capocci; Michaela Bustuchina Vlaicu; Eimad Shotar; Bertrand Mathon; Mariette Delaitre; Kévin Premat; Maichael Talaat; Atika Talbi; Anne-Laure Boch; Stéphanie Lenck; Alexandre Carpentier; Vincent Degos; Nader Antoine Sourour; Frédéric Clarençon
Journal:  Clin Neuroradiol       Date:  2021-11-22       Impact factor: 3.156

Review 5.  Gamma Knife radiosurgery for cerebral arteriovenous malformations: a systematic review and meta-analysis.

Authors:  Musa China; Amisha Vastani; Ciaran Scott Hill; Cornel Tancu; Patrick J Grover
Journal:  Neurosurg Rev       Date:  2022-02-18       Impact factor: 2.800

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.